Burning Mouth Syndrome Clinical Trial
Official title:
Research of a Biological Marker for Chronic Orofacial Pain: Dosage of Opiorphin in Patients With Burning Mouth Syndrome
If epidemiological studies indicate relatively low prevalence reported in the general population, idiopathic burning mouth syndrome (BMS) is a common condition among certain groups of the population: 30% of menopausal women experience oral burning to varying degrees . Despite significant progress made in recent years, in understanding the physiopathogeny, treatment options remain limited and disappointing,resulting in an impairment of the quality of life. Given the chronic nature of idiopathic burning mouth syndrome, the need to identify the causes and effective treatment modalities for subjects suffering is essential.
Idiopathic burning mouth syndrome (BMS) is a chronic orofacial pain condition in which the
pain is felt as intense, located on the tongue and the oral mucosa with no known cause. The
pain may last for years and present treatments are of little effect. BMS is primarily a
feminine disease, affecting women during or following menopause, suggesting an
etiopathogenic role of the sexual hormones potentiating a local salivary factor. An
anxiodepressive component is often associated with the disease. Recently, a molecule named
opiorphin has been identified in human saliva. In animals, this molecule has shown potent
analgesic properties comparable to those of morphine. The hypothesis of the investigators is
that this molecule is in lower quantity in the saliva of persons suffering BMS and that this
decrease causes oral burning sensations.
The main objective of the study is to test the hypothesis of a decrease of opiorphin levels
in the saliva of patients suffering from primary BMS compared to a group of control
subjects. The main judgment criteria is the level of salivary opiorphin in ng/mL.
The proposed study is a multicentric, simple blinded case controlled study. The
investigators will collect the data from 21 primary BMS patients and 21 control subjects
matched in sex, age, and hormonal status (menopause). The alpha risk is 0.5% and the power
of the study is 90%.
Criteria for inclusion : BMS patients will be suffering for more than 4 months from burning
pain in the tongue or oral mucosa with no organic trouble detectable by anamnesis, clinical
evaluation and biological testing.
The design of the study includes three sessions for all subject of both groups; the maximum
duration of participation for a subject is 8 weeks and the total duration of the study is 24
months There are two investigation centers.
;
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04475614 -
Therapeutic Options for Treatment of Burning Mouth Syndrome
|
N/A | |
Completed |
NCT00374673 -
Efficacy of Transcranial Magnetic Stimulation (TMS) in Chronic Idiopathic Pain Disorders
|
Phase 3 | |
Completed |
NCT02964728 -
Botulinum Toxin in Burning Mouth Syndrome
|
Phase 2 | |
Completed |
NCT04535973 -
Hormonal Status and Quality of Life in Female Postmenopausal Patients With Burning Mouth Syndrome
|
||
Recruiting |
NCT06040190 -
Effect of Treatments on Pain and Quality of Life in Individual With Burning Mouth Syndrome
|
Phase 4 | |
Not yet recruiting |
NCT05059418 -
Burning Mouth Syndrome - New Diagnostic Criteria and Treatment
|
N/A | |
Recruiting |
NCT01867151 -
Effect of Gluten Free Diet in Patients With Burning Mouth Syndrome
|
N/A | |
Completed |
NCT05872789 -
Impact of Diazepam 1% Oral Gel Efficacy in Burning Mouth Syndrome
|
N/A | |
Completed |
NCT05871580 -
Effect to the Photobiomodulation in the Burning Mouth Syndrome
|
N/A | |
Recruiting |
NCT05309070 -
The Efficacy of N-acetyl-cysteine in the Treatment of Burning Mouth Syndrome
|
N/A | |
Completed |
NCT05399238 -
Thermography and Burning Mouth Syndrome
|
||
Completed |
NCT02382029 -
Acupuncture Versus Clonazepam in Burning Mouth Syndrome
|
Phase 0 | |
Completed |
NCT02580734 -
Efficacy of Melatonin in Burning Mouth Syndrome (BMS)
|
N/A | |
Recruiting |
NCT05819697 -
Reducing Patient Memory Recall in the Burning Mouth Patient Population
|
||
Completed |
NCT02757612 -
Study Evaluating the Laser Diode Effect Burning Mouth Syndrome
|
N/A | |
Completed |
NCT00862576 -
A Study of the Association of Sleep Dysfunction and Burning Mouth Syndrome
|
N/A | |
Not yet recruiting |
NCT04189367 -
Treatment of Burning Mouth Syndrome With Integration of Traditional Chinese Medicine and Western Medicine
|
Phase 3 | |
Completed |
NCT00001524 -
Thalidomide to Treat Oral Lesions in HIV-Infected Patients
|
Phase 2 | |
Recruiting |
NCT04481841 -
Head Yuanshi Dian Therapy in Burning Mouth Syndrome
|
Early Phase 1 | |
Completed |
NCT05309681 -
Salivary Melatonin Levels and Sleep Quality in Patients With Burning Mouth Syndrome
|